Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.
Frequently asked questions
What sector does Akari Therapeutics PLC (AKTX) operate in?
Akari Therapeutics PLC belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Akari Therapeutics PLC (AKTX) current stock price?
As of the latest data, Akari Therapeutics PLC stock price is $7.52, with a previous close of $7.54. Akari Therapeutics PLC lost -$0.02 in the last trading session, representing a -0.27% loss.
What is Akari Therapeutics PLC (AKTX) current market capitalization?
Akari Therapeutics PLC market cap is approximately 13.16 million.
What is Akari Therapeutics PLC (AKTX) EBITDA?
Akari Therapeutics PLC EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -15.25 million.
Does Akari Therapeutics PLC (AKTX) pay dividends?
No. Akari Therapeutics PLC does not pay a dividend.
When is Akari Therapeutics PLC (AKTX) next earnings report?
Akari Therapeutics PLC is expected to release its next earnings report on June 30, 2026.
What is Akari Therapeutics PLC (AKTX) beta (volatility) score?
Akari Therapeutics PLC has a beta of 1.387, suggesting it is more volatile than the market.
